← Back to Search

Sodium-glucose cotransporter 2 (SGLT2) inhibitor

canagliflozin for Type 2 Diabetes

Phase 4
Waitlist Available
Led By Lawrence S Phillips, MD
Research Sponsored by Foundation for Atlanta Veterans Education and Research, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 weeks
Awards & highlights

Study Summary

This trial is testing whether canagliflozin is safe and effective in reducing the need for mealtime insulin in people with type 2 diabetes.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Frequency and severity of hypoglycemia
Number of patients who discontinue all pre-meal medications for at least one meal per day
Number of patients who replace mealtime insulin with an oral agent for at least one meal per day
+2 more

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: canagliflozinActive Control1 Intervention
Subjects randomized to this arm will start with 100 mg tablet and increase to 300 mg tablet at Visit 4 if well tolerated.
Group II: placeboPlacebo Group1 Intervention
Subjects randomized to this arm will start with 100 mg tablet and increase to 300 mg tablet at Visit 4 if well tolerated.

Find a Location

Who is running the clinical trial?

Foundation for Atlanta Veterans Education and Research, Inc.Lead Sponsor
5 Previous Clinical Trials
635 Total Patients Enrolled
Janssen Scientific Affairs, LLCIndustry Sponsor
159 Previous Clinical Trials
580,478 Total Patients Enrolled
Lawrence S Phillips, MDPrincipal InvestigatorAtlanta VA Medical Center
2 Previous Clinical Trials
2,065 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Diabetes CareJournal
Increased Mortality of Patients with Diabetes Reporting Severe Hypoglycemia
McCoy, Rozalina G., Holly K. Van Houten, Jeanette Y. Ziegenfuss, Nilay D. Shah, Robert A. Wermers, and Steven A. Smith. 2012. “Increased Mortality of Patients with Diabetes Reporting Severe Hypoglycemia”. Diabetes Care. American Diabetes Association. doi:10.2337/dc11-2054.
Diabetes CareJournal
Canagliflozin Compared with Sitagliptin for Patients with Type 2 Diabetes Who Do Not Have Adequate Glycemic Control with Metformin Plus Sulfonylurea
Schernthaner, Guntram, Jorge L. Gross, Julio Rosenstock, Michael Guarisco, Min Fu, Jacqueline Yee, Masato Kawaguchi, William Canovatchel, and Gary Meininger. 2013. “Canagliflozin Compared with Sitagliptin for Patients with Type 2 Diabetes Who Do Not Have Adequate Glycemic Control with Metformin Plus Sulfonylurea”. Diabetes Care. American Diabetes Association. doi:10.2337/dc12-2491.
Diabetes, Obesity and MetabolismJournal
Meta-analysis of Individual Patient Data to Assess the Risk of Hypoglycaemia in People with Type 2 Diabetes Using NPH Insulin or Insulin Glargine
Home, P. D., A. Fritsche, S. Schinzel, and M. Massi-Benedetti. 2010. “Meta-analysis of Individual Patient Data to Assess the Risk of Hypoglycaemia in People with Type 2 Diabetes Using NPH Insulin or Insulin Glargine”. Diabetes, Obesity and Metabolism. Wiley. doi:10.1111/j.1463-1326.2010.01232.x.
DiabetesJournal
Oscillating Glucose Is More Deleterious to Endothelial Function and Oxidative Stress Than Mean Glucose in Normal and Type 2 Diabetic Patients
Ceriello, Antonio, Katherine Esposito, Ludovica Piconi, Michael A. Ihnat, Jessica E. Thorpe, Roberto Testa, Massimo Boemi, and Dario Giugliano. 2008. “Oscillating Glucose Is More Deleterious to Endothelial Function and Oxidative Stress Than Mean Glucose in Normal and Type 2 Diabetic Patients”. Diabetes. American Diabetes Association. doi:10.2337/db08-0063.
~4 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top